Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Medicine information AVTOZMA162mg solution for injection in pre-filled pen
- Product code:
- W71395001
- Quantity:
- 4
- Indicated for:
- autoimmune inflammatory diseases
- Route of administration:
- injectable
- Substance:
- tocilizumab (monoclonal antibody)
- ATC
- L04AC07 — Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Interleukin inhibitors
Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, used in the treatment of autoimmune inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and cytokine release syndrome. By blocking the IL-6 receptor, tocilizumab reduces inflammation and abnormal immune responses.
Tocilizumab is administered either intravenously or subcutaneously, depending on the specific indication and patient preference. The dose and frequency of administration are adjusted based on body weight and disease severity.
Common side effects include upper respiratory tract infections, high blood pressure, headache, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as serious infections or gastrointestinal perforations may occur. Regular monitoring of clinical parameters is essential during treatment.
Tocilizumab is an important therapeutic option for patients with chronic inflammatory diseases, contributing to symptom relief and improved quality of life.
Tocilizumab is administered either intravenously or subcutaneously, depending on the specific indication and patient preference. The dose and frequency of administration are adjusted based on body weight and disease severity.
Common side effects include upper respiratory tract infections, high blood pressure, headache, and elevated liver enzyme levels. In rare cases, severe adverse reactions such as serious infections or gastrointestinal perforations may occur. Regular monitoring of clinical parameters is essential during treatment.
Tocilizumab is an important therapeutic option for patients with chronic inflammatory diseases, contributing to symptom relief and improved quality of life.
General data about AVTOZMA162mg
- Substance:
- tocilizumab
- Date of latest medicines list:
- 01-10-2026
- Product code:
- W71395001
- Strength:
- 162mg
- Pharmaceutical form:
- solution for injection in pre-filled pen
- Quantity:
- 4
- Product type:
- Generic medicine
- Price:
- 2905.48 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for tocilizumab
Strengths available for tocilizumab
- 162mg
- 200mg
- 20mg/ml
- 400mg
- 80mg
Official documents
The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.
- Added to database:
- 04/04/2025
- Source record updated:
- 18/09/2026
Warnings:
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Reimbursement lists for AVTOZMA162mg Celltrion
G17 (C1) - Major collagenosis (systemic lupus erythematosus, scleroderma)
- Price
- 2905.48 RON
- Copayment
- 2876.14 RON
- Patient payment
- 29.34 RON